The primary focus is on emerging biotechnology, pharmaceutical, medical devices, and other innovative
technologies and services. The strategy will use individual stock of smaller emerging companies but may
invest in larger companies opportunistically. The strategy may also use ETFs as well.
PVG’s Emerging Healthcare Strategy seeks to outperform the Nasdaq Biotech Index (NBI). Over the long-term,
is expected that the strategy will significantly outperform the S&P 500. The primary focus of the strategy
investing in emerging companies that may not have revenues and may be funding clinical trials in
of the development of a new drug or device.